Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Immune Resolution After Staphylococcus Aureus Bacteremia

Active, not recruiting

Conditions: Immune Response To Sepsis
Staphylococcus Aureus Infection

First Posted Date: 2013-06-18

Last Posted Date: 2024-07-26

Lead Sponsor: University of Chicago

Target Recruit Count: 102

Registration Number: NCT01879761

Locations: 🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States

Inositol in Trichotillomania

Phase 2

Completed

Conditions: Trichotillomania
Hair Pulling

Interventions: Drug: Placebo
Drug: Inositol

First Posted Date: 2013-06-11

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT01875445

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

The Effects of Buprenorphine on Responses to Verbal Tasks

Early Phase 1

Completed

Conditions: Basic Science

Interventions: Drug: Placebo
Drug: Buprenorphine 0.2 MG Sublingual Tablet
Drug: Buprenorphine 0.4 MG Sublingual Tablet

First Posted Date: 2013-05-22

Last Posted Date: 2019-08-01

Lead Sponsor: University of Chicago

Target Recruit Count: 48

Registration Number: NCT01860287

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Allergic Rhinitis Changes the Sinus Microbiome

Phase 4

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Placebo nasal spray
Drug: QNASL

First Posted Date: 2013-05-13

Last Posted Date: 2020-10-09

Lead Sponsor: University of Chicago

Target Recruit Count: 39

Registration Number: NCT01852513

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effects of MDMA on Social and Emotional Processing

Not Applicable

Completed

Conditions: Drug Addiction

Interventions: Drug: Within-subjects (MDMA)
Drug: Within-subjects (oxytocin)
Drug: Within-subjects (placebo)

First Posted Date: 2013-05-08

Last Posted Date: 2014-12-18

Lead Sponsor: University of Chicago

Target Recruit Count: 65

Registration Number: NCT01849419

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Salivary Gland Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma of the Larynx

Interventions: Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: fluorouracil
Drug: hydroxyurea
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Radiation: hyperfractionated radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2013-05-06

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 48

Registration Number: NCT01847326

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: WT1 126-134 peptide vaccine
Biological: basiliximab
Drug: Montanide ISA 51 VG
Drug: poly ICLC
Other: laboratory biomarker analysis

First Posted Date: 2013-04-29

Last Posted Date: 2018-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 7

Registration Number: NCT01842139

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Acute Myeloid Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Hairy Cell Leukemia
Secondary Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Biological: therapeutic allogeneic lymphocytes
Other: laboratory biomarker analysis

First Posted Date: 2013-04-25

Last Posted Date: 2019-08-07

Lead Sponsor: University of Chicago

Target Recruit Count: 77

Registration Number: NCT01839916

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: azacitidine
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2013-04-24

Last Posted Date: 2020-05-15

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT01839240

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-03-22

Last Posted Date: 2024-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 76

Registration Number: NCT01816971

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 2 locations

Home Terms & Conditions Privacy Policy